Compare NMTC & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMTC | PLUR |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 25.5M |
| IPO Year | 2010 | 2001 |
| Metric | NMTC | PLUR |
|---|---|---|
| Price | $3.35 | $2.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $11.90 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 25.5K | 12.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.43 | 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,097,692.00 | $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | $31.90 | $293.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 163.47 | ★ 309.82 |
| 52 Week Low | $0.55 | $2.00 |
| 52 Week High | $5.40 | $5.96 |
| Indicator | NMTC | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 32.73 |
| Support Level | $0.69 | N/A |
| Resistance Level | $4.87 | $2.58 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 36.75 | 16.67 |
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.